Please login to the form below

Not currently logged in
Email:
Password:

chronic myeloid leukaemia

This page shows the latest chronic myeloid leukaemia news and features for those working in and with pharma, biotech and healthcare.

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Daurismo cleared for those too frail for chemo. Pfizer has added to a run of new product approvals for acute myeloid leukaemia (AML) with an FDA nod for Daurismo, the first ... indications such as myelodysplastic syndrome (MDS), acute lymphoblastic

Latest news

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    Meanwhile, Novartis got the go-ahead for new labelling for its chronic myeloid leukaemia (CML drug Tasigna (nilotinib. ... Patients with early (chronic) phase CML who have been taking Tasigna for three years or more and whose leukaemia has responded to

  • Novartis' orphan drug Tasigna wins EU expanded indication Novartis' orphan drug Tasigna wins EU expanded indication

    The CML medication can now treat paediatric patients. Novartis has claimed another regulatory milestone for its chronic myeloid leukaemia (CML) drug Tasigna (nilotinib), winning approval for its use to treat children ... The European Commission approved

  • Takeda's gamble on Ariad pays off with Alunbrig approval Takeda's gamble on Ariad pays off with Alunbrig approval

    Iclusig - approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) - has been a slow-grower, largely because of safety concerns and while it has started to gain traction it

  • Takeda agrees $5.2bn deal to buy Ariad Takeda agrees $5.2bn deal to buy Ariad

    Sale of chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) therapy Iclusig for were pegged back by safety concerns that emerged in 2013 but since then have started to gain

  • Pfizer's SMO inhibitor boosts survival in blood cancer trial Pfizer's SMO inhibitor boosts survival in blood cancer trial

    Glasdegib (previously known as PF-04449913) extended overall survival in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) to almost nine months when added to low-dose ... indications such as MDS, acute lymphoblastic

More from news
Approximately 5 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    8. Daurismo – a new wave of AML treatment. After many years with no new therapies, the treatment of acute myeloid leukaemia (AML) is set for rapid change, thanks to a wave ... as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL),

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase

  • Deal Watch May 2016 Deal Watch May 2016

    In addition Incyte was granted an exclusive licence to Inclusig [the only approved BCR-ABL inhibitor with activity against the T315I mutation approved in Europe for chronic myeloid leukaemia (CML) and ... acute lymphoblastic leukaemia (ALL)] in Europe

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Research &licensing agreement. 142.5. Boston Heart Diagnostics / Eurofins Scientific. Diagnostics tests for chronic conditions including cardiovascular diseases and diabetes. ... JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL,

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    December 2012 for its use in two rare types of cancer: chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). ... As for the future of Iclusig in leukaemia, Ariad is keen to roll out the drug in

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Helen Parfitt joins Research Partnership Helen Parfitt joins Research Partnership

    She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its

  • Ariad founder Harvey Berger to retire as CEO and chairman Ariad founder Harvey Berger to retire as CEO and chairman

    Under his leadership, Ariad brought Iclusig to the market for the treatment of patients with refractory chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia, approved in the US, EU,

  • Hugh Cole leaves Shire for Ariad Hugh Cole leaves Shire for Ariad

    This includes its only current marketed product Iclusig, which is recommended to treat chronic myeloid leukaemia and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukaemia.

  • Jonathan Dickinson joins Ariad from BMS Jonathan Dickinson joins Ariad from BMS

    Will lead launch of chronic myeloid leukaemia treatment Iclusig. Ariad Pharmaceuticals has appointed Bristol-Myers Squibb's (BMS) Jonathan Dickinson as general manager of its European business. ... He joins at an important time for Ariad in Europe as it

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics